JP5948056B2 - 側方流動核酸検出器 - Google Patents
側方流動核酸検出器 Download PDFInfo
- Publication number
- JP5948056B2 JP5948056B2 JP2011518870A JP2011518870A JP5948056B2 JP 5948056 B2 JP5948056 B2 JP 5948056B2 JP 2011518870 A JP2011518870 A JP 2011518870A JP 2011518870 A JP2011518870 A JP 2011518870A JP 5948056 B2 JP5948056 B2 JP 5948056B2
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- complex
- target nucleic
- double
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims description 183
- 108020004707 nucleic acids Proteins 0.000 title claims description 113
- 102000039446 nucleic acids Human genes 0.000 title claims description 113
- 238000012360 testing method Methods 0.000 claims description 113
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 62
- 239000003795 chemical substances by application Substances 0.000 claims description 50
- 238000003556 assay Methods 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 25
- 230000003100 immobilizing effect Effects 0.000 claims description 23
- 238000001514 detection method Methods 0.000 claims description 22
- 230000002934 lysing effect Effects 0.000 claims description 22
- 230000000295 complement effect Effects 0.000 claims description 21
- 239000002131 composite material Substances 0.000 claims description 19
- 239000003398 denaturant Substances 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 12
- 239000011325 microbead Substances 0.000 claims description 10
- 230000009089 cytolysis Effects 0.000 claims description 9
- 238000003752 polymerase chain reaction Methods 0.000 claims description 9
- 230000000692 anti-sense effect Effects 0.000 claims description 8
- 239000004816 latex Substances 0.000 claims description 8
- 229920000126 latex Polymers 0.000 claims description 8
- 230000003321 amplification Effects 0.000 claims description 6
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 6
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 230000035945 sensitivity Effects 0.000 claims description 5
- 238000011144 upstream manufacturing Methods 0.000 claims description 5
- 238000007826 nucleic acid assay Methods 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 claims 2
- 239000000523 sample Substances 0.000 description 64
- 230000032258 transport Effects 0.000 description 20
- 238000007689 inspection Methods 0.000 description 19
- 239000007788 liquid Substances 0.000 description 18
- 230000027455 binding Effects 0.000 description 17
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 16
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 239000012491 analyte Substances 0.000 description 9
- 239000011324 bead Substances 0.000 description 9
- 239000000975 dye Substances 0.000 description 8
- 229960002685 biotin Drugs 0.000 description 7
- 235000020958 biotin Nutrition 0.000 description 7
- 239000011616 biotin Substances 0.000 description 7
- 108090001008 Avidin Proteins 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 230000002452 interceptive effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 238000001429 visible spectrum Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 125000003147 glycosyl group Chemical group 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000011246 composite particle Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000003869 genetically modified organism Nutrition 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 108010087904 neutravidin Proteins 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 238000012123 point-of-care testing Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000001044 red dye Substances 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101001128393 Homo sapiens Interferon-induced GTP-binding protein Mx1 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100031802 Interferon-induced GTP-binding protein Mx1 Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102000010750 Metalloproteins Human genes 0.000 description 1
- 108010063312 Metalloproteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102000004903 Troponin Human genes 0.000 description 1
- 108090001027 Troponin Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000011365 complex material Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical class 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 238000000892 gravimetry Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000012125 lateral flow test Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 108091000699 pea lectin Proteins 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- -1 saliva Chemical class 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000008646 thermal stress Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8087908P | 2008-07-15 | 2008-07-15 | |
| US61/080,879 | 2008-07-15 | ||
| US9893508P | 2008-09-22 | 2008-09-22 | |
| US61/098,935 | 2008-09-22 | ||
| US17905909P | 2009-05-18 | 2009-05-18 | |
| US61/179,059 | 2009-05-18 | ||
| US12/502,662 US8614101B2 (en) | 2008-05-20 | 2009-07-14 | In situ lysis of cells in lateral flow immunoassays |
| US12/502,626 | 2009-07-14 | ||
| US12/502,626 US8669052B2 (en) | 2008-06-10 | 2009-07-14 | Lateral flow nucleic acid detector |
| US12/502,662 | 2009-07-14 | ||
| PCT/US2009/050645 WO2010009203A2 (en) | 2008-07-15 | 2009-07-15 | Lateral flow nucleic acid detector |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011528229A JP2011528229A (ja) | 2011-11-17 |
| JP2011528229A5 JP2011528229A5 (OSRAM) | 2014-05-08 |
| JP5948056B2 true JP5948056B2 (ja) | 2016-07-06 |
Family
ID=41550997
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011518870A Expired - Fee Related JP5948056B2 (ja) | 2008-07-15 | 2009-07-15 | 側方流動核酸検出器 |
| JP2011518872A Pending JP2012503170A (ja) | 2008-07-15 | 2009-07-15 | 側方流動イムノアッセイにおけるインサイツでの細胞の溶解 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011518872A Pending JP2012503170A (ja) | 2008-07-15 | 2009-07-15 | 側方流動イムノアッセイにおけるインサイツでの細胞の溶解 |
Country Status (3)
| Country | Link |
|---|---|
| EP (2) | EP2313775A4 (OSRAM) |
| JP (2) | JP5948056B2 (OSRAM) |
| WO (2) | WO2010009206A2 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104777298B (zh) * | 2010-04-26 | 2017-10-31 | 艾博生物医药(杭州)有限公司 | 一种检测装置 |
| ES2564290T3 (es) | 2010-11-02 | 2016-03-21 | Kypha, Inc. | Inmunoensayo de flujo lateral para la activación de complemento y métodos de uso para evaluación del sitio de atención de trastornos asociados a complemento |
| CN108107211B (zh) * | 2011-07-22 | 2020-06-09 | 阿赛斯生物股份有限公司 | 用于改善的侧向流动测定法的单一垫条 |
| CN104053992B (zh) * | 2012-01-16 | 2016-12-14 | 皇家飞利浦有限公司 | 确定包括细胞的体液中的靶分子的存在 |
| JP2013198482A (ja) * | 2012-02-22 | 2013-10-03 | Nippon Meat Packers Inc | 核酸の検出方法 |
| KR101409263B1 (ko) * | 2012-10-16 | 2014-07-02 | 바디텍메드 주식회사 | 서브패드를 구비한 측방유동 분석용 스트립 및 이에 사용되는 측방유동 분석용 카트리지 |
| EP2927688A4 (en) * | 2012-11-28 | 2016-07-27 | Furukawa Electric Co Ltd | IMMUNOCHROMATOGRAPHY AND DETECTOR AND REAGENT FOR USE THEREIN |
| DK2909331T3 (da) * | 2013-03-07 | 2019-08-19 | Rapid Pathogen Screening Inc | Fremgangsmåde og indretning til kombineret detektering af virus- og bakterieinfektioner |
| JP6177009B2 (ja) * | 2013-06-03 | 2017-08-09 | 株式会社日立ハイテクノロジーズ | 血球破壊試薬及びそれを用いる血球破壊方法 |
| EP3733868A3 (en) * | 2013-10-28 | 2021-01-13 | DOTS Technology Corp. | Allergen detection |
| KR20160131011A (ko) * | 2014-03-12 | 2016-11-15 | 엠씨10, 인크 | 분석물의 변화의 정량화 |
| US10808287B2 (en) | 2015-10-23 | 2020-10-20 | Rapid Pathogen Screening, Inc. | Methods and devices for accurate diagnosis of infections |
| CN107478829A (zh) * | 2017-09-29 | 2017-12-15 | 亳州市新健康科技有限公司 | 一种基于双竞争免疫层析法的毒品检测试剂盒及其制备工艺 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994016108A1 (en) * | 1993-01-15 | 1994-07-21 | The Public Health Research Institute Of The City Of New York, Inc. | Sensitive nucleic acid sandwich hybridization assays and kits |
| WO1997023781A1 (en) * | 1995-12-22 | 1997-07-03 | Universal Healthwatch, Inc. | Fecal test method and device |
| US6358752B1 (en) * | 1996-09-27 | 2002-03-19 | Cornell Research Foundation, Inc. | Liposome-enhanced test device and method |
| DE19816550A1 (de) * | 1997-12-24 | 1999-06-24 | Roche Diagnostics Gmbh | Universell verwendbarer Aufbau eines Analysenelements und dessen Einsatz zur Analytbestimmung |
| WO2000029112A1 (en) * | 1998-11-18 | 2000-05-25 | Orchid Biosciences, Inc. | One-step nucleic acid dipstick device with movable membrane |
| WO2000079283A1 (en) * | 1999-06-23 | 2000-12-28 | Cornell Research Foundation, Inc. | Dehydration/rehydration of marked liposomes on a test device |
| WO2002004122A2 (en) * | 2000-07-07 | 2002-01-17 | Helen Lee | Improved stability of hybridisation interactions in dipstick assays |
| GB0016836D0 (en) * | 2000-07-07 | 2000-08-30 | Lee Helen | Improved dipstick assays (1) |
| SE0103072D0 (sv) * | 2001-09-17 | 2001-09-17 | Pharmacia Diagnostics Ab | Multi-analyte assay device with multi-spot detection zone |
| EP1525055A1 (en) * | 2002-07-12 | 2005-04-27 | British Biocell International Limited | Lateral flow assay device and method |
| US20040241779A1 (en) * | 2003-02-24 | 2004-12-02 | Piasio Roger N. | Dry chemistry, lateral flow-reconstituted chromatographic enzyme-driven assays |
| ES2363501T3 (es) * | 2003-05-07 | 2011-08-05 | Coris Bioconcept Sprl | Dispositivo oligocromático de un paso y procedimiento de uso. |
| JP2005017248A (ja) * | 2003-06-30 | 2005-01-20 | Asahi Breweries Ltd | 免疫クロマトグラフィー用分析装置 |
| US20060019406A1 (en) * | 2004-07-23 | 2006-01-26 | Ning Wei | Lateral flow device for the detection of large pathogens |
| EP1657550A1 (en) * | 2004-11-10 | 2006-05-17 | Coris Bioconcept SPRL | Double-sided device for multiplex dipstick immunodiagnostic |
| NL1027737C2 (nl) * | 2004-12-14 | 2006-06-16 | Teststrip B V | Chromatografische analyse-inrichting en test kit. |
| US20060240569A1 (en) * | 2005-04-20 | 2006-10-26 | Becton, Dickinson And Company | Semi-quantitative immunochromatographic device |
| US7618810B2 (en) * | 2005-12-14 | 2009-11-17 | Kimberly-Clark Worldwide, Inc. | Metering strip and method for lateral flow assay devices |
| US8007999B2 (en) * | 2006-05-10 | 2011-08-30 | Theranos, Inc. | Real-time detection of influenza virus |
-
2009
- 2009-07-15 WO PCT/US2009/050653 patent/WO2010009206A2/en not_active Ceased
- 2009-07-15 JP JP2011518870A patent/JP5948056B2/ja not_active Expired - Fee Related
- 2009-07-15 WO PCT/US2009/050645 patent/WO2010009203A2/en not_active Ceased
- 2009-07-15 EP EP09798691A patent/EP2313775A4/en not_active Withdrawn
- 2009-07-15 JP JP2011518872A patent/JP2012503170A/ja active Pending
- 2009-07-15 EP EP09798690A patent/EP2313527A4/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP2313775A2 (en) | 2011-04-27 |
| EP2313527A2 (en) | 2011-04-27 |
| WO2010009206A3 (en) | 2010-05-14 |
| WO2010009206A2 (en) | 2010-01-21 |
| EP2313775A4 (en) | 2012-03-14 |
| EP2313527A4 (en) | 2012-11-21 |
| JP2012503170A (ja) | 2012-02-02 |
| WO2010009203A3 (en) | 2010-04-08 |
| WO2010009203A2 (en) | 2010-01-21 |
| JP2011528229A (ja) | 2011-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5948056B2 (ja) | 側方流動核酸検出器 | |
| US8669052B2 (en) | Lateral flow nucleic acid detector | |
| US9121849B2 (en) | Lateral flow assays | |
| Song et al. | Rapid and sensitive detection of β-agonists using a portable fluorescence biosensor based on fluorescent nanosilica and a lateral flow test strip | |
| US8614101B2 (en) | In situ lysis of cells in lateral flow immunoassays | |
| JP5855572B2 (ja) | サンプル圧縮機を用いた複数面の側方流動アッセイ | |
| US8609433B2 (en) | Multiplanar lateral flow assay with sample compressor | |
| JP5890789B2 (ja) | 分析物を検出するための装置および方法 | |
| KR100804202B1 (ko) | 크로마토그래피 측정 시스템 | |
| US8470608B2 (en) | Combined visual/fluorescence analyte detection test | |
| EP0171150A2 (en) | Method and apparatus for assaying with optional reagent quality control | |
| CN100420947C (zh) | 用单一捕获剂定量检测特异性分析物的方法及其试剂盒 | |
| WO2015088455A1 (en) | Aptamer-gated nanoparticles for lateral flow assays | |
| WO2008140620A2 (en) | Ultra sensitive biomolecule detection using double stranded dna co-loaded gold nanoparticles and co-immobilized capture molecules | |
| EP3929307A1 (en) | Methods for detecting the presence of sepsis | |
| Jain et al. | Fabrication of paper-based immunochromatography assay | |
| ATAKISI¹ et al. | LATERAL FLOW IMMUNOASSAY: CREATIVE DIAGNOSTICS DISCOVERY | |
| ATAKISI et al. | LATERAL FLOW IMMUNOASSAY: CREATIVE DIAGNOSTICS DISCOVERY FOR VETERINARY MEDICINE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120530 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120531 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131218 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20140318 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140806 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141208 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20141224 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20150227 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160316 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160606 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5948056 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |